← Human Trials & Peer-Reviewed Studies
Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Plain-language guide to PMID 36306151 (2023): double-blind randomized controlled trial study of Liraglutide, fat loss, obesity & body recomposition.
Key Facts
- PMID
- 36306151
- Journal
- Diabetes, obesity & metabolism
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Mashayekhi M et al. (14 authors)
- DOI
- 10.1111/dom.14903
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Liraglutide in the context of fat loss, obesity & body recomposition.
Who Took Part
Treatment with drug was double blind and placebo-controlled.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.
Individuals with obesity and prediabetes were randomized to 14 weeks of the GLP-1R agonist liraglutide, hypocaloric diet or the dipeptidyl peptidase-4 inhibitor sitagliptin in a 2:1:1 ratio.
The primary outcomes were measures of endothelial function: flow-mediated vasodilation (FMD), plasminogen activator inhibitor-1 (PAI-1) and urine albumin-to-creatinine ratio (UACR).
What Was Measured
PubMed files the paper under topics including Incretins, Liraglutide, Plasminogen Activator Inhibitor 1, Prediabetic State, Fibrinolysis, Insulin Resistance and Diet, Reducing.
The authors tagged it with the keywords DPP4 inhibitor, GLP-1 receptor agonist, cardiovascular disease, dietary intervention, incretin physiology and randomized trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in people with fat loss, obesity & body recomposition.
The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.